4.7 Article

The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension

Journal

CHEST
Volume 141, Issue 2, Pages 354-362

Publisher

AMER COLL CHEST PHYSICIANS
DOI: 10.1378/chest.11-0676

Keywords

-

Funding

  1. Actelion Pharmaceuticals US, Inc.
  2. Actelion
  3. American Heart Association
  4. Raver
  5. National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI)
  6. Novartis
  7. Pfizer
  8. United Therapeutics
  9. Medtronic
  10. Gilead
  11. Lilly/Los
  12. Encysive Pharmaceuticals
  13. Lung Rx
  14. Eli Lilly Co

Ask authors/readers for more resources

Background: In pulmonary arterial hypertension (PAH), survival predictions can be important for optimization of therapeutic strategies. The present study aimed to validate a quantitative algorithm for predicting survival derived from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) and develop a simplified calculator for everyday clinical use. Methods: Prospectively collected data from patients with newly diagnosed (<3 months) World Health Organization group I pulmonary hypertension enrolled in the REVEAL Registry were used to validate a predictive algorithm for 1-year survival. Model calibration was evaluated by comparing algorithm-predicted survival with observed Kaplan-Meier estimates for the overall validation cohort and for five risk groups. Similarly, the risk discriminators for the simplified calculator were compared with those of the quantitative algorithm. Results: The validation cohort comprised 504 individuals with mean SD 6-min walk distance 308 128 m, and 61.5% were functional class III. The proportion of patients surviving 1 year fell within the range predicted by the model (95.1%, 91.5%, 84.6%, 76.3%, and 58.2%, respectively) among patients in the low (predicted survival 95%), average (90% to < 95%), moderate (85% to < 90%), high (70% to < 85%), and very high (< 70%) risk strata. Predicted and observed 1-year survival were similar across risk stratum, and the c-index indicated good discrimination for both the full equation (0.726) and the simplified risk calculator (0.724). Conclusions: The REVEAL Registry predictive algorithm and simplified risk score calculator are well calibrated and demonstrate good discriminatory ability in patients with newly or previously diagnosed PAH.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available